12:00 AM
 | 
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onglyza saxagliptin regulatory update

Bristol-Myers and AstraZeneca said FDA extended the PDUFA data for an NDA for Onglyza saxagliptin to treat Type II diabetes to July 30 from April 30. Bristol-Myers said the agency did not give...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >